First Paediatric Use Marketing Authorisation Granted
pharmafile | September 14, 2011 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Wainwright Associates
The European Commission has granted the first ever children’s medicine to hold a new Paediatric Use Marketing Authorisation (PUMA). The medicine called Buccolam is now specifically licensed to treat convulsions and epileptic seizures in children.
A PUMA will cover the appropriate formulation for the paediatric population. Once granted, the PUMA will benefit from ten years of market protection as a reward for the development.
This change is a leap forward in helping to improve the safety, quality and availability of children’s medicines in the EU.
The development of medicines for children also require a Paediatric Investigation Plan (PIP) which must discuss all paediatric subsets to be agreed by the Paediatric Committee.
If you require assistance with a Paediatric Use Marketing Authorisation or Paediatric Investigation Plan please contact us at enquiries@wainwrightassociates.co.uk or telephone +44 (0)1628 530554.
Related Content
Submission of labels and leaflets in the UK
The MHRA has announced procedural changes concerning the requirement to submit full-colour mock-ups of labels …
On-going Medicine evaluation Information to be published by European Medicines Agency
Following the recommendations on transparency published by the European Heads of Medicines Agencies (HMA) and …
MHRA Inspections of CROs
In accordance with the provisions of the new pharmacovigilance legislation, as per Directive 2010/84/EU, EU …